相关实验视频

Updated: Jan 9, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

超越单疗法:在淋巴瘤管理中整合免疫检查点抑制剂的多模式策略

Yuxiao Li¹, Ruixin Zheng¹, Bing Pan¹

¹Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.

Frontiers in immunology

|December 8, 2025

概括

免疫检查点抑制剂 (ICI) 在淋巴瘤中表现出不同程度的成功. 结合ICI和其他治疗方法可以改善结果,克服某些淋巴瘤的耐药性,尽管存在潜在的副作用.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

免疫检查点抑制剂 (ICI) 已经改变了淋巴瘤治疗,但在霍奇金淋巴瘤 (HL) 和非霍奇金淋巴瘤 (NHL) 亚型之间,疗效不同.
编程细胞死亡蛋白1 (PD-1) /编程死亡连接体1 (PD-1/PD-L1) 途径抑制剂在HL和某些NHL中有效,但在其他类型如扩散大B细胞淋巴瘤和大多数外围T细胞淋巴瘤中效果较差.
其他免疫检查点也在淋巴瘤进展和T细胞枯竭中发挥作用,表明它们的治疗潜力.

研究的目的:

审查ICI与常规疗法,向药物和淋巴瘤新方法结合的机制基础和临床应用.
综合结合方法的证据,为淋巴瘤免疫治疗中的治疗决策提供框架.
突出挑战和优化基于ICI的组合疗法的未来方向.

主要方法:

文献综述综合了ICI组合在淋巴瘤中的机制论证和临床试验数据.
结合ICI与化疗,放射治疗和向药物的协同效应分析.
对免疫组合疗法改善反应和生存率的证据的评估.

主要成果:

将PD-1抑制剂与化疗或放射治疗结合使用,在特定淋巴瘤亚型中显示出更好的反应和生存率.
协同作用的组合显示出克服治疗耐药性和增强抗瘤免疫力的潜力.
免疫组合疗法可以在某些淋巴瘤亚型中获得更高的疗效,尽管它们与免疫相关的不良事件增加有关.

结论:

将ICI与补充疗法相结合,为改善淋巴瘤治疗结果提供了显著的潜力.
需要进一步的研究来开发预测性生物标志物,并优化针对组合疗法的免疫相关不良事件的管理.
严格的机制性探索和临床验证对于最大限度地提高淋巴瘤免疫疗法的治疗指数和反应的持久性至关重要.

关键词:

在 CTLA-4 中.在PD-1/PD-L1中.组合疗法治疗组合治疗.免疫检查点抑制剂免疫检查点抑制剂淋巴瘤淋巴瘤是什么

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...